Loading
Life sciences · Journal article
International Journal of Molecular Sciences · October 27, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Chimeric antigen receptor T (CAR-T) cell therapy has completely reshaped the therapeutic landscape for some blood cancers, including B-cell lymphoma, myeloma, and acute lymphoblastic leukemia. However, the complications associated with this powerful therapy are preventing it from being used more widely. This review explores the underlying biology, clinical signs, and current treatments for the three major early CAR-T cell therapy-associated toxicities: cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, and immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome. Here, we outline key findings from preclinical animal models, data from multicenter clinical trials, and real-world patient cohort study data to delineate how infused cells and different host-derived and blood–brain barrier disruptions contribute to these adverse effects. A growing body of evidence is revealing that the patient’s own monocytes and macrophages, not just the infused CAR-T cells, may contribute to driving systemic toxicities primarily by releasing interleukin-1 (IL-1) and IL-6. A more thorough and mechanistically detailed understanding of CAR-T cell therapy-associated toxicity is needed to develop better predictive tools and treatment strategies so that patients derive the greatest antitumor benefits with the lowest risk of severe treatment-related complications.